摘要
背景:结合优化认知(阿尔茨海默病评估量表-认知子量表,ADAS-Cog)和阿尔茨海默病萎缩标志物在临床试验中跟踪进展Y比目前使用的方法具有更大的敏感性,在最近的多项试验中产生了阴性结果。此外,必须澄清子组件之间的关系。S是通过认知和影像学测试,来解决阿尔茨海默病的症状和解剖变异。 方法:采用潜变量分析法,对ADAS-Cog评定的认知功能损害与脑萎缩的关系进行深入研究。开发了一种用于阿尔茨海默病的生物标志物。Imer的临床试验结合了认知和萎缩标记。 结果:脑内特定区域的萎缩与记忆、语言和实践等认知领域的损害密切相关。所提出的生物标记物显示出明显的更好的效果在模拟试验和一个真实世界的问题中,追踪认知障碍的进展比ADAS-Cog更敏感。该生物标志物还改进了mci患者的选择(78.8 4.9%例特异性)。城市在80%的敏感性),将演变为阿尔茨海默氏病的临床试验。 结论:该生物标记物通过显著提高检测治疗的敏感性,提高了轻度认知功能障碍(MCI)阶段临床试验的有效性。NT效应和改善MCI患者的选择将演变为阿尔茨海默病。
关键词: 潜变量模型,阿尔茨海默病评估量表,阿尔茨海默病临床试验,脑萎缩,认知障碍,轻度认知障碍。
Current Alzheimer Research
Title:A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials
Volume: 15 Issue: 5
关键词: 潜变量模型,阿尔茨海默病评估量表,阿尔茨海默病临床试验,脑萎缩,认知障碍,轻度认知障碍。
摘要: Background: Combining optimized cognitive (Alzheimer's Disease Assessment Scale- Cognitive subscale, ADAS-Cog) and atrophy markers of Alzheimer's disease for tracking progression in clinical trials may provide greater sensitivity than currently used methods, which have yielded negative results in multiple recent trials. Furthermore, it is critical to clarify the relationship among the subcomponents yielded by cognitive and imaging testing, to address the symptomatic and anatomical variability of Alzheimer's disease.
Method: Using latent variable analysis, we thoroughly investigated the relationship between cognitive impairment, as assessed on the ADAS-Cog, and cerebral atrophy. A biomarker was developed for Alzheimer's clinical trials that combines cognitive and atrophy markers.
Results: Atrophy within specific brain regions was found to be closely related with impairment in cognitive domains of memory, language, and praxis. The proposed biomarker showed significantly better sensitivity in tracking progression of cognitive impairment than the ADAS-Cog in simulated trials and a real world problem. The biomarker also improved the selection of MCI patients (78.8±4.9% specificity at 80% sensitivity) that will evolve to Alzheimer's disease for clinical trials.
Conclusion: The proposed biomarker provides a boost to the efficacy of clinical trials focused in the mild cognitive impairment (MCI) stage by significantly improving the sensitivity to detect treatment effects and improving the selection of MCI patients that will evolve to Alzheimer’s disease.
Export Options
About this article
Cite this article as:
A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials, Current Alzheimer Research 2018; 15 (5) . https://dx.doi.org/10.2174/1567205014666171106150309
DOI https://dx.doi.org/10.2174/1567205014666171106150309 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology <i>Rhizoma Coptidis</i> for Alzheimer’s Disease and Vascular Dementia: A Literature Review
Current Vascular Pharmacology Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimers Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Semantic Dementia: A Mini-Review
Mini-Reviews in Medicinal Chemistry Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Methylated MicroRNA Genes of the Developing Murine Palate
MicroRNA The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry